Heidelberg University Researchers Present Data On MiRview Mets Assay At Neuroweek Conference
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the results of a two-phased, post-marketing validation study using the Company’s miRview™ mets assay have been presented at the “Neuroweek” conference in Mannheim, Germany by lead investigator, Dr. Wolf C. Mueller from the Department of Neuropathology at Heidelberg University in Germany, “Neuroweek” is a joint meeting of German medical societies focused on neurology-related disease management and research. It consists of the Annual Congress of the German Society of Neurology, the Annual Conference of the German Society of Neuropathology and Neuroanatomy, as well as the Annual Meetings of the German Societies of Neurosurgeons, Neuropediatricians and Neuroradiologists.
The study consisted of a proof-of-concept phase and a validation phase. In the proof-of-concept phase, brain and spine metastases from known primary tumors were analyzed with the miRview™ mets assay. In the validation phase of the study, a cohort of brain and spine metastatic samples of true Cancer of Unknown Primary (CUP) patients were studied, and concordance between results generated by miRview™ mets and the clinical and pathological evaluation was examined.
Results from the validation phase demonstrated that primary origin prediction from miRview™ mets was in agreement with the clinical or pathological evaluation in 80% of the cases.
“Knowing the origin of a metastasis affects treatment decisions, and CUP patients may undergo a wide range of costly and time-consuming tests to identify the primary site of origin, often to no avail. Consequently, we are extremely pleased with the positive results of this study, which demonstrate the ability of miRview™ mets to assist physicians in accurately identifying the origin of metastases in true CUP patients,” noted Kenneth A. Berlin, President and CEO of Rosetta Genomics. “This is the second post-marketing validation study we have completed with a leading cancer center focusing on miRview™ mets and its ability to accurately identify the origin of metastases in CUP, and we are gratified to see the consistently strong performance of our microRNA-based assay. Literature has shown microRNAs to be highly tissue specific, and we believe that our sensitive, proprietary microRNA technology is enabling us to harness their power to develop diagnostic tools with high accuracy for the benefit of patients worldwide.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV